8-K: CERo Secures $7M in Series E Preferred Stock Funding

CERo Therapeutics Holdings, Inc. has entered into a Securities Purchase Agreement to raise up to $7 million through the issuance of Series E convertible preferred stock to accredited investors.

Summary

• CERo Therapeutics Holdings, Inc. (CERO) has entered into a Securities Purchase Agreement with accredited investors for a private placement of Series E convertible preferred stock.
• The company will issue up to 9,750 shares of Series E convertible preferred stock, with an aggregate purchase price of up to $7 million.
• Approximately $1.8 million will be funded at the initial closing.
• The Series E Preferred Stock has a stated value of $1,000 per share and ranks senior to common stock, junior to Series A preferred, and pari passu with Series C and D preferred stock.
• Holders of Series C and Series D preferred stock consented to the Series E issuance pari passu, in exchange for a reduction of their conversion price to $1.76.
• The Series E Preferred Stock is convertible into common stock at a fixed conversion price of $4.1625, subject to adjustments.
• Alternate conversion options exist, allowing conversion at the lesser of the fixed conversion price or 95% of the lowest VWAP (or 90% upon a Triggering Event), with a floor price of $1.00.
• The company is obligated to seek stockholder approval for the issuance of conversion shares at a price below the conversion price, with deadlines for proxy filings and a stockholder meeting by December 31, 2025.
• Proceeds from the sale will be used for general corporate purposes, explicitly excluding satisfaction of certain indebtedness, redemption/repurchase of securities, or settlement of outstanding litigation.
• The company will file a registration statement to allow for the resale of common stock issuable upon conversion of the Series E Preferred Stock.

Sentiment

Score: 4

Explanation: The capital raise provides essential funding for the company's operations, which is a positive. However, the highly dilutive terms of the Series E preferred stock, including variable conversion prices and a low floor, along with the reduction in conversion price for prior preferred series, indicate significant concessions and potential negative impact on existing common shareholders. The need for a capital raise itself, coupled with strict covenants, suggests financial pressure.

Positives

• Secures up to $7 million in new capital, with $1.8 million at the initial closing, providing necessary funding for general corporate purposes.
• Existing Series C and Series D preferred holders consented to the new Series E preferred stock ranking pari passu, indicating cooperation among investors.
• The company will maintain a transfer agent participating in FAST, facilitating electronic share transfers for investors.
• The company is committed to registering the resale of the conversion shares, providing liquidity for investors.

Negatives

• The Series E Preferred Stock includes highly dilutive conversion features, such as conversion at 95% (or 90% upon a Triggering Event) of the lowest volume-weighted average price (VWAP) during a five-day period, with a floor price of $1.00.
• The company is required to seek stockholder approval for the issuance of conversion shares at a price below the conversion price, indicating potential for significant dilution to existing common stockholders.
• Failure to meet registration deadlines or maintain effectiveness of the registration statement will result in "Registration Delay Payments" to holders, incurring additional costs for the company.
• The company is prohibited from certain actions, such as issuing other dilutive securities or undertaking fundamental transactions, without the consent of "Required Holders," which could limit future strategic flexibility.
• The reduction of the conversion price for Series C and Series D preferred stock to $1.76, while securing consent for Series E, represents additional dilution for common stockholders.

Risks

• Dilution Risk: The conversion features of the Series E Preferred Stock, particularly the variable conversion price based on VWAP and the $1.00 floor, pose a significant risk of substantial dilution to existing common stockholders.
• Regulatory Compliance Risk: Failure to timely file or maintain effectiveness of the registration statement for resale of conversion shares will trigger financial penalties (Registration Delay Payments).
• Operational Constraints: Covenants restrict the company from incurring certain indebtedness, creating liens, making restricted payments, transferring assets outside the ordinary course, or changing its business nature, which could limit operational and strategic flexibility.
• Stockholder Approval Risk: The company needs stockholder approval for certain dilutive issuances, and failure to obtain this by specified deadlines (December 31, 2025, then March 1, 2026, then semi-annually) could impact future capital raising or operations.
• Liquidation Preference Risk: In a liquidation event, Series E holders (pari passu with Series C and D, junior to Series A) are entitled to a 125% premium on their conversion amount, potentially leaving less for common stockholders.
• Market Price Manipulation Risk: The company acknowledges that buyers may engage in hedging and/or trading activities, including short sales, which "can reduce the value of the existing stockholders equity interest in the Company."
• Going Private Transaction Risk: The Series E Preferred Stock terms include provisions for a "Going Private Transaction," which could lead to the purchase and/or cancellation of all common stock solely for cash, potentially at a disadvantageous price for common stockholders.

Future Outlook

The company expects to use the proceeds from the Series E preferred stock sale for general corporate purposes. It is committed to timely SEC filings and maintaining its Nasdaq listing. The company anticipates seeking stockholder approval for certain dilutive issuances, with a preliminary proxy statement filing by October 31, 2025, and a stockholder meeting by December 31, 2025, if prior consent is not obtained.

Management Comments

• The Company acknowledges and agrees that each Buyer is acting solely in the capacity of an arms length purchaser with respect to the Transaction Documents and the transactions contemplated hereby and thereby.
• The Company acknowledges that its obligation to issue the Conversion Shares pursuant to the terms of the Series E Preferred Shares in accordance with this Agreement and the Certificate of Designations is absolute and unconditional regardless of the dilutive effect that such issuance may have on the ownership interests of other stockholders of the Company.
• The Company acknowledges that such aforementioned hedging and/or trading activities [by buyers] do not constitute a breach of this Agreement, the Certificate of Designations or any other Transaction Document or any of the documents executed in connection herewith or therewith.

Industry Context

This capital raise by CERo Therapeutics Holdings, Inc. is typical for biotechnology companies, which often rely on private placements and convertible securities to fund research, development, and operational expenses. The dilutive nature of the preferred stock, with variable conversion prices and a low floor, reflects the high-risk, high-reward investment landscape in the biotech sector, where early-stage companies require significant capital before achieving profitability or market approval for their products. The need for ongoing capital raises and the associated dilution are common challenges in this industry.

Corporate Governance

Stakeholder Impact

• Shareholders (Common Stock): Significant potential for dilution due to the variable conversion price of Series E Preferred Stock and the reduction in conversion price for Series C and D preferred stock. Their equity interest could be substantially reduced.
• Series E Preferred Stock Holders: Benefit from senior ranking, fixed and variable conversion options (including discounts to market price), a floor price, and a 125% redemption premium in certain events, providing strong downside protection and upside potential. They also gain significant control through covenants.
• Series C and D Preferred Stock Holders: Benefit from a reduced conversion price ($1.76), enhancing their potential returns and maintaining pari passu ranking with the new Series E.
• Company Management: Secures crucial funding for operations but operates under strict covenants and potential dilution pressures, requiring careful navigation of capital structure and investor relations.
• Creditors: The covenants restricting additional indebtedness and liens, and the use of proceeds, could offer some protection by limiting further encumbrances on company assets, but the overall financial health and ability to repay debt depend on the effective use of the raised capital.

Next Steps

• Company to issue and sell Initial Series E Preferred Shares at the Initial Closing Date.
• Company to file a Form D with the SEC and comply with Blue Sky laws for the Securities.
• Company to file a Current Report on Form 8-K and issue a press release disclosing the material terms of the transactions by the first business day after the agreement date.
• Company to prepare and file an initial Registration Statement on Form S-3 (or S-1) covering the resale of all Registrable Securities by the Filing Deadline (30 calendar days after Initial Closing Date).
• Company to use best efforts to cause the Registration Statement to become effective by the Effectiveness Deadline (90 or 120 calendar days after Initial Closing Date).
• Company to seek stockholder approval for the issuance of conversion shares at a price below the conversion price, with a preliminary proxy statement filing by October 31, 2025, a definitive proxy by November 30, 2025, and a stockholder meeting by December 31, 2025.
• If stockholder approval is not obtained by December 31, 2025, the company will hold additional stockholder meetings semi-annually until approval is secured.
• Company to maintain its Nasdaq listing for common stock and secure listing for conversion shares.
• Company to maintain a transfer agent participating in FAST.

Key Dates

Recommendation

The filing details a capital raise that provides essential funding for CERo Therapeutics, which is a positive for its continued operations. However, the terms of the Series E convertible preferred stock are highly dilutive for existing common shareholders, featuring variable conversion prices that can go as low as $1.00, and a 125% redemption premium. The reduction in conversion price for Series C and D preferred stock further exacerbates this dilution. While the funding is critical, the significant concessions made to investors, coupled with strict covenants, suggest a challenging financial position and potential for substantial future dilution. Without more comprehensive financial statements and a clearer strategic roadmap, a 'hold' recommendation is appropriate, advising investors to monitor the company's execution, future dilution, and progress towards profitability or key milestones.

Keywords

Series E Preferred Stock, Convertible Securities, Private Placement, PIPE Investment, Dilution, Registration Rights, SEC Filing, Corporate Finance, Capital Raise, Biotechnology, CERO Therapeutics